XML 8 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document And Entity Information - USD ($)
Dec. 31, 2022
Apr. 21, 2023
Jun. 30, 2022
Document Information [Line Items]      
Entity, Registrant Name NOVABAY PHARMACEUTICALS, INC.    
Document, Type 10-K/A    
Document, Annual Report true    
Document, Period End Date Dec. 31, 2022    
Current Fiscal Year End Date --12-31    
Document, Fiscal Period Focus FY    
Document, Fiscal Year Focus 2022    
Document, Transition Report false    
Entity, File Number 001-33678    
Entity, Incorporation, State or Country Code DE    
Entity, Tax Identification Number 68-0454536    
Entity, Address, Address Line One 2000 Powell Street, Suite 1150    
Entity, Address, City or Town Emeryville    
Entity, Address, State or Province CA    
Entity, Address, Postal Zip Code 94608    
City Area Code 510    
Local Phone Number 899-8800    
Title of 12(b) Security Common Stock    
Trading Symbol NBY    
Security Exchange Name NYSE    
Entity, Well-known Seasoned Issuer No    
Entity, Voluntary Filers No    
Entity, Current Reporting Status Yes    
Entity, Interactive Data, Current Yes    
Entity, Emerging Growth Company false    
Entity, Filer Category Non-accelerated Filer    
Entity, Small Business true    
ICFR Auditor Attestation Flag false    
Entity, Shell Company false    
Entity, Public Float     $ 10,875,498
Entity, Common Stock Shares, Outstanding   2,194,444  
Auditor Name WithumSmith+Brown, PC    
Auditor Firm ID 100    
Auditor Location San Francisco, CA    
Amendment Description NovaBay Pharmaceuticals, Inc. is filing this Amendment No. 1 on Form 10-K/A (this “Form 10-K/A”) to its Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the “Original Form 10-K”) that was filed with the Securities and Exchange Commission (“SEC”) on March 31, 2023 for the sole purpose of including the information required by Part III of Form 10-K. This Part III information was previously omitted from the Original Form 10-K in reliance on General Instruction G(3) to Form 10-K, which permits the information in Part III to be incorporated in Form 10-K by reference to the Company’s definitive proxy statement if such statement is filed no later than 120 days after the end of our fiscal year.   As required by Rule 12b-15, in connection with this Form 10-K/A, the Company’s Principal Executive Officer and Principal Financial Officer are providing Rule 13a-14(a) certifications included herein.   Except as explicitly set forth herein, this Form 10-K/A does not purport to modify or update the disclosures in, or exhibits to, the Original Form 10-K or to update the Original Form 10-K to reflect events occurring after the date of such filing.    
Amendment Flag true    
Entity, Central Index Key 0001389545